# Fulvestrant

## Faslodex inj 250mg/5mL

| 藥物代碼 | IFAS |
| :--- | :--- |
| 適應症 | Breast cancer, metastatic, breast cancer, advanced or metastatic \(second-line endocrine-based combination therapy\) |
| 副作用 | &gt;10%:Central nervous system: Fatigue \(8% to 29%\), headache \(8% to 20%\)Gastrointestinal: Nausea \(10% to 28%\), diarrhea \(19%\), constipation \(5% to 16%\), stomatitis \(13%\)Hematologic & oncologic: Anemia \(13% to 40%; grade 3: 2%\)Hepatic: Increased liver enzymes \(&gt;15%; grades 3/4: 1% to 2%\)Infection: Infection \(31%; including nasopharyngitis, upper respiratory infection, urinary tract infection, influenza, bronchitis, rhinitis, conjunctivitis, pneumonia, sinusitis, cystitis, oral herpes, respiratory tract infection\)Local: Pain at injection site \(12%; including neuralgia, peripheral neuropathy, sciatica\)1% to 10%:Dermatologic: Alopecia \(6%\), skin rash \(6%\), xeroderma \(1%\)Endocrine & metabolic: Hot flash \(7%\)Gastrointestinal: Decreased appetite \(8%\), anorexia \(6%\), vomiting \(6%\), dysgeusia \(3%\)Hematologic & oncologic: Decreased platelet count \(10%\), leukopenia \(5%; grade 3: 1%; grade 4: 1%\), neutropenia \(4%; grade 3: 1%\), febrile neutropenia \(1%; grade 4: 1%\)Neuromuscular & skeletal: Ostealgia \(9%\), arthralgia \(8%\), back pain \(8%\), limb pain \(7%\), musculoskeletal pain \(6%\), weakness \(5% to 6%\)Ophthalmic: Blurred vision \(2%\), dry eye syndrome \(2%\), increased lacrimation \(1%\)Respiratory: Cough \(5%\), dyspnea \(4%\), epistaxis \(2%\) |
| 禁忌 | a\)  hypersensitivity to fulvestrant or to any of its componentsb\)  suspected or known pregnancyPrecautionsA\)  hepatic impairmentSerious Adverse Effects:a\)  Anemiab\)  Angioedema |
| 藥物保存方式 | 2-8 C |
| 用法用量 | Breast cancer, metastatic \(postmenopausal women; HR positive\): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly. Breast cancer, advanced or metastatic \(second-line endocrine-based combination therapy\): Adult females \(HR positive, HER-2 negative\): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with palbociclib \(and an LHRH agonist \[eg, goserelin\] if pre- or perimenopausal\); continue until disease progression or unacceptable toxicity. Note: Refer to Palbociclib monograph for dosing in combination with fulvestrant. |
| 肝功能異常 | 需 調 整 劑 量  重度肝功能不全者為禁忌。 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 投與Faslodex應以兩次連續的5毫升在臀部肌肉處緩慢注射\(1-2分鐘注射\)，一邊一次。 |

## Faslodex inj 250mg/5mL \(sample\)

| 藥物代碼 | IFAS0 |
| :--- | :--- |
| 適應症 | Breast cancer, metastatic, breast cancer, advanced or metastatic \(second-line endocrine-based combination therapy\) |
| 副作用 | &gt;10%:Central nervous system: Fatigue \(8% to 29%\), headache \(8% to 20%\)Gastrointestinal: Nausea \(10% to 28%\), diarrhea \(19%\), constipation \(5% to 16%\), stomatitis \(13%\)Hematologic & oncologic: Anemia \(13% to 40%; grade 3: 2%\)Hepatic: Increased liver enzymes \(&gt;15%; grades 3/4: 1% to 2%\)Infection: Infection \(31%; including nasopharyngitis, upper respiratory infection, urinary tract infection, influenza, bronchitis, rhinitis, conjunctivitis, pneumonia, sinusitis, cystitis, oral herpes, respiratory tract infection\)Local: Pain at injection site \(12%; including neuralgia, peripheral neuropathy, sciatica\)1% to 10%:Dermatologic: Alopecia \(6%\), skin rash \(6%\), xeroderma \(1%\)Endocrine & metabolic: Hot flash \(7%\)Gastrointestinal: Decreased appetite \(8%\), anorexia \(6%\), vomiting \(6%\), dysgeusia \(3%\)Hematologic & oncologic: Decreased platelet count \(10%\), leukopenia \(5%; grade 3: 1%; grade 4: 1%\), neutropenia \(4%; grade 3: 1%\), febrile neutropenia \(1%; grade 4: 1%\)Neuromuscular & skeletal: Ostealgia \(9%\), arthralgia \(8%\), back pain \(8%\), limb pain \(7%\), musculoskeletal pain \(6%\), weakness \(5% to 6%\)Ophthalmic: Blurred vision \(2%\), dry eye syndrome \(2%\), increased lacrimation \(1%\)Respiratory: Cough \(5%\), dyspnea \(4%\), epistaxis \(2%\) |
| 禁忌 | a\)  hypersensitivity to fulvestrant or to any of its componentsb\)  suspected or known pregnancyPrecautionsA\)  hepatic impairmentSerious Adverse Effects:a\)  Anemiab\)  Angioedema |
| 藥物保存方式 | 2-8 C |
| 用法用量 | Breast cancer, metastatic \(postmenopausal women; HR positive\): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly. Breast cancer, advanced or metastatic \(second-line endocrine-based combination therapy\): Adult females \(HR positive, HER-2 negative\): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with palbociclib \(and an LHRH agonist \[eg, goserelin\] if pre- or perimenopausal\); continue until disease progression or unacceptable toxicity. Note: Refer to Palbociclib monograph for dosing in combination with fulvestrant. |
| 肝功能異常 | 需 調 整 劑 量  重度肝功能不全者為禁忌。 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 投與Faslodex應以兩次連續的5毫升在臀部肌肉處緩慢注射\(1-2分鐘注射\)，一邊一次。 |

